IQVIA (NYSE:IQV) Insider W Richard Staub Sells 5,500 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

IQVIA Stock Performance

Shares of IQV opened at $228.18 on Wednesday. The firm’s 50 day moving average price is $197.37 and its two-hundred day moving average price is $186.67. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $251.36. The firm has a market cap of $37.56 billion, a P/E ratio of 28.31, a PEG ratio of 1.97 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the business posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.61 EPS for the current fiscal year.

IQVIA declared that its board has authorized a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

IQV has been the topic of several research reports. Royal Bank Of Canada boosted their target price on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Barclays reiterated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. HSBC reissued a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research report on Thursday, July 9th. Finally, Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Institutional Investors Weigh In On IQVIA

A number of institutional investors and hedge funds have recently made changes to their positions in IQV. Brighton Jones LLC grew its stake in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC raised its position in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after acquiring an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in IQVIA in the second quarter valued at $514,000. First Trust Advisors LP grew its position in shares of IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after acquiring an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC increased its stake in shares of IQVIA by 5.4% during the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after purchasing an additional 1,155 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.